Sahajanand Medical Technologies Ltd
Sahajanand Medical Technologies Ltd: Summons Received Under CGST Act
REGULATORY
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 24 Oct 2026, 12:04 PM IST · BSE ID: 95fa0066-9b82-4e97-9e8d-e1199a8a1fd7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is being asked by tax authorities to provide information regarding payments made to its foreign branches for testing new medicines.
🤖 AI Summary
- Company received summons under Section 70 of CGST Act from DGGI, Mumbai.
- Inquiry relates to GST compliance for reimbursements to foreign subsidiaries.
- Summons dated 16 October 2026, received on 23 October 2026.
- Company expects no material financial impact and is cooperating fully.
🏢 How This Affects the Company
The company has stated that this summons does not have any material financial impact at this stage.
The company is fully cooperating with the authorities and will provide all necessary information required.
The inquiry introduces a regulatory compliance risk, though the company anticipates no material financial or operational impact.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Shareholders should monitor future company disclosures regarding this matter.
👤
Who Is Affected
All shareholders are potentially affected by regulatory inquiries, though the company has stated there is no material financial impact.
🔍
Management Signal
Management's prompt disclosure and emphasis on cooperation signals a commitment to transparency and regulatory compliance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Further disclosures from the company on the inquiry's progress.
Updates on the verification of books of accounts by DGGI.
Any potential financial or operational impacts if they arise.
MEDIUM RISK
A summons under Section 70 of the CGST Act indicates a formal inquiry into tax compliance.
💡 Investor Takeaway
Sahajanand Medical Technologies Ltd. received a GST summons concerning foreign subsidiary reimbursements for clinical trials. The company is cooperating and anticipates no material financial impact.
❓ Frequently Asked Questions
What action has Sahajanand Medical Technologies Ltd. received?
Sahajanand Medical Technologies Ltd. has received a summons issued under Section 70 of the Central Goods and Services Tax Act, 2017.
Who issued the summons to Sahajanand Medical Technologies Ltd.?
The summons was issued by the Superintendent/Appraiser/Senior Intelligence Officer of DGGI, Mumbai Zonal Unit.
What is the subject of the inquiry by DGGI?
The inquiry relates to giving evidence in relation to GST compliance for reimbursements made to foreign subsidiaries for clinical trials.
What is the financial impact of this summons on Sahajanand Medical Technologies Ltd.?
The company has stated that this summons does not have any material financial impact on the Company at this stage.
When was the summons issued and received by the company?
The summons was dated 16 October 2026 and received by the company on 23 October 2026.
Questions based on this BSE filing only. For information purposes.